Introduction {#s1}
============

Late in December 2019 and early in January 2020, reports of a very progressive pneumonia-like respiratory syndrome, starting in Wuhan, China, induced global health concerns ([@B1]). Soon after the onset of disease, it was found that the pathogen was a new member of the coronaviridae family, named SARS-COV-2 which is now called 2019-n-CoV ([@B2]). The respiratory syndrome caused by 2019-n-CoV is called COVID-19. COVID-19 is characterized by low-grade fever, cough, dyspnea, lymphopenia, and ground-glass opacities on chest CT scan ([@B3], [@B4]). COVID-19 is a highly contagious disease, probably an aerosol born one, with human to human transmission capacity which has implicated many countries all around the world ([@B5]). In this review article, we systematically surveyed case reports and case series from many countries in the world to give a picture of the epidemiology, clinical presentations, laboratory changes, imaging findings, diagnostic criteria, treatments, outcomes, prognostic factors, and risk factors of COVID-19 in hospitalized patients.

Methods {#s2}
=======

This review conforms to the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement ([@B6]).

Search Strategy
---------------

We carried out systematic searches of the literature in the following bibliographical databases: PubMed/Medline, Embase, and Web of Science. Search criteria included case reports and case series articles published up to April 24, 2020, and there were no restrictions regarding publication language. We used Google Translate for eligible articles published in languages other than English. The search terms for our review were: COVID-19, severe acute respiratory syndrome coronavirus 2, novel coronavirus, SARS-CoV-2, nCoV disease, SARS2, COVID-19, 2019-nCoV, coronavirus disease-19, coronavirus disease 2019, and 2019 novel coronavirus.

Study Selection
---------------

Studies included in the review met the following criteria: prospective or retrospective descriptive case reports and case series of COVID-19 in the hospital setting which included diagnostic methods, clinical manifestations, laboratory features, treatment, and outcomes. Articles describing experimental approaches as well as reviews and publications without peer-review processes were excluded.

All potentially relevant articles were screened in two stages for eligibility. In the first stage, the titles and abstracts of potentially relevant articles were screened independently by two reviewers (YF, PJ). In the second stage of assessment, the full text of those abstracts which met the inclusion criteria was retrieved and independently reviewed by the same authors. Disagreements and technical uncertainties were discussed and resolved between review authors (AT, SH, MA, MJN).

Data Extraction
---------------

The extracted data included bibliographic data, patient demographics (e.g., age and gender), radiological and laboratory findings, treatment protocols, and medical consequences. Two authors (AT, SH) independently extracted the data from the selected studies. The data was jointly reconciled, and disagreements were discussed and resolved between review authors (YF, PJ, MA, MJN).

Quality Assessment {#s3}
==================

The critical appraisal checklist for case reports provided by the Joanna Briggs Institute (JBI) was used to perform a quality assessment of the studies ([@B7]).

Results {#s4}
=======

As illustrated in [Figure 1](#F1){ref-type="fig"}, our systematic search resulted in an initial number of 6,004 of potentially relevant articles, of which 1,033 were excluded by title and abstract evaluation. Applying the inclusion/exclusion criteria to the full-text documents, 80 articles were eligible for inclusion in the systematic review. 42 case reports and 38 case series from 19 countries were identified with a total of 417 unique cases of COVID-19 with a mean age of 48 years ([Table 1](#T1){ref-type="table"}). The included case reports were published because of the following reasons: they reported (1) new CT findings; (2) new clinical manifestations; (3) new laboratory findings, (4) new treatment outcomes; (5) atypical manifestations and some were the first one in a specific country. Based on the JBI tool, the included studies had a low risk of bias. RT-PCR COVID-19 was present in 79 (95%) articles as inclusion criteria. In addition to RT-PCR, a CT scan served as a diagnostic tool in 16 (19%) of papers. Reported comorbidities included hypertension, diabetes, cardiovascular disease, and pulmonary disease. Hypertension was investigated the most, studied in 22/83 (26.5%) of papers. Of the 16 COVID-19 positive patients found in the studies investigating hypertension, 44 patients were hypertensive (19%) ([Table 2](#T2){ref-type="table"}). Lymphopenia was reported in 24 studies which identified 83/185 (45%) of COVID-19 positive patients. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). CT images commonly displayed ground-glass opacification (GGO) patterns (82%) as well as bilateral lung involvement (66%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19. We found 11/83 (13.2%) reports on Acute Respiratory Distress Syndrome (ARDS), 18 of 86 (21%) investigated cases had ARDS. Mortality outcomes were difficult to assess; only 10 studies showed mortality data in which 17/108 (16%) COVID-19 patients died. A wide range of therapeutic modalities was tried across studies, with antiviral treatments being the most used.

![Flow chart of study selection for inclusion in the systematic review.](fmed-07-00231-g0001){#F1}

###### 

Characteristics of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                     **Country**   **Published time**   **Type of study**   **Mean age**          **Male/**\   **No. of patient (s)**   **Diagnostic methods**
                                                                                                                  **Female**                            
  ---------------------------------- ------------- -------------------- ------------------- --------------------- ------------ ------------------------ ------------------------
  Kim et al. ([@B8])                 South Korea   19, Feb, 2020        Case report         45                    1M,1F        2                        RT-PCR/CT-scan

  Yu et al. ([@B9])                  China         18, Feb, 2020        Case report         74.2                  2M, 2F       4                        RT-PCR

  Bastola et al. ([@B10])            Nepal         10, Feb, 2020        Case report         32                    M            1                        RT-PCR

  Duan and Qin ([@B11])              China         4, Feb, 2020         Case report         46                    F            1                        RT-PCR/CT-scan

  Fang et al. ([@B12])               China         19, Feb, 2020        Case report         47                    M            1                        RT-PCR/CT-scan

  Han et al. ([@B13])                China         19, Feb, 2020        Case report         47                    M            1                        RT-PCR/CT-scan

  Wei et al. ([@B14])                China         25, Feb, 2020        Case report         62                    M            1                        RT-PCR/CT-scan

  Holshue et al. ([@B15])            USA           5, Mar, 2020         Case report         35                    M            1                        RT-PCR

  Lim et al. ([@B16])                South Korea   14, Feb, 2020        Case report         54                    M            1                        RT-PCR/CT-scan

  Shi et al. ([@B17])                China         4, Feb, 2020         Case report         42                    M            1                        RT-PCR/CT-scan

  Silverstein et al. ([@B18])        Canada        13, Feb, 2020        Case report         56                    M            1                        RT-PCR

  Wei et al. ([@B19])                China         17, Feb, 2020        Case report         40                    F            1                        RT-PCR

  Wu et al. ([@B20])                 China         3, Feb, 2020         Case report         41                    M            1                        RT-PCR

  Xu et al. ([@B21])                 China         17, Feb, 2020        Case report         50                    M            1                        RT-PCR

  Winichakoon et al. ([@B22])        Thailand      26, Feb, 2020        Case report         28                    M            1                        RT-PCR

  Zhan et al. ([@B23])               China         28, Jan, 2020        Case report         38                    1M, 1F       2                        RT-PCR

  Fang et al. ([@B24])               China         7, Feb, 2020         Case report         38.5                  1M,1F        2                        RT-PCR/CT-scan

  Lin et al. ([@B25])                China         11, Feb, 2020        Case report         37                    M            2                        RT-PCR/CT-scan

  Liu et al. ([@B26])                Taiwan        12, Mar, 2020        Case report         51                    1M, 1F       2                        RT-PCR

  Phan et al. ([@B27])               Vietnam       27, Feb, 2020        Case report         Father: 65, Son: 27   M            2                        RT-PCR

  Pongpirul et al. ([@B28])          Thailand      12, Mar, 2020        Case report         51                    M            1                        RT-PCR

  Hao et al. ([@B29])                China         2, Feb, 2020         Case report         60                    M            1                        RT-PCR/CT-scan

  Hao and Li ([@B30])                China         17, Feb, 2020        Case report         58                    M            1                        RT-PCR

  Zhang et al. ([@B31])              China         11, Feb, 2020        Case report         3 months              1M           1                        RT-PCR

  Bai et al. ([@B32])                China         17, Feb, 2020        Case series         53.4                  3M/4F        7                        RT-PCR

  Cai et al. ([@B33])                China         4, Feb, 2020         Case report         7                     1M           1                        RT-PCR

  Zeng et al. ([@B34])               China         17, Feb, 2020        Case report         17 days               1M           1                        RT-PCR

  Chan et al. ([@B35])               China         24, Jan, 2020        Case series         46                    3M,3F        6                        RT-PCR

  Chen et al. ([@B36])               China         12, Feb, 2020        Case series         29.8                  F            9                        RT-PCR/CT-scan

  Wei et al. ([@B37])                China         21, Feb, 2020        Case series         6 months              2 M, 7F      9                        RT-PCR

  Qin et al. ([@B38])                China         22, Feb, 2020        Case series         55.5                  2M, 2F       4                        CT-scan

  Wang et al. ([@B39])               China         9, Feb, 2020         Case series         44.2                  3M, 1F       4                        RT-PCR/CT-scan

  Xie et al. ([@B40])                China         12, Feb, 2020        Case series         48.4                  M4, F1       5                        RT-PCR

  Yoon et al. ([@B41])               Korea         18, Feb, 2020        Case series         54                    4M, 5F       9                        CT-scan

  Stoecklin et al. ([@B42])          France        13, Feb, 2020        Case series         36.3                  2M, 1F       3                        RT-PCR

  Rothe et al. ([@B43])              Germany       5, Mar, 2020         Case series         33                    NR           5                        RT-PCR

  Bai et al. ([@B44])                China         21, Feb, 2020        Case series         42-57                 1M, 5F       6                        RT-PCR

  Tong et al. ([@B45])               China         9, May, 2020         Case series         31                    4M, 3F       7                        RT-PCR

  Feng et al. ([@B46])               China         16, Feb, 2020        Case series         7                     5M/10F       15                       RT-PCR

  Zhang et al. ([@B47])              China         15, Feb, 2020        Case series         36                    5M/4F        9                        RT-PCR

  Liu et al. ([@B48])                China         17, Feb, 2020        Case series         35                    10M/20F      30                       RT-PCR

  Albarello et al. ([@B49])          Italy         20, Feb, 2020        Case series         66.5                  1M/1F        2                        RT-PCR

  Asadollahi-Amin et al. ([@B50])    Iran          7, Apr, 2020         Case report         44                    M            1                        RT-PCR

  Bhat et al. ([@B51])               USA           11, Apr, 2020        Case series         54.5                  6M/2F        8                        RT-PCR

  Chen et al. ([@B52])               China         1, Apr, 2020         Case series         52.6                  2M/1F        3                        RT-PCR

  Wang et al. ([@B53])               China         9, Apr, 2020         Case series         42                    11M/15F      26                       RT-PCR

  Liu et al. ([@B54])                China         16, Apr, 2020        Case series         54                    2M/1F        3                        RT-PCR

  Lu et al. ([@B55])                 China         19, Mar, 2020        Case series         NM                    NM           3                        RT-PCR

  Lin et al. ([@B56])                China         22, Feb, 2020        Case report         61                    M            1                        RT-PCR

  Mousavi et al. ([@B57])            Afghanistan   5, Apr, 2020         Case report         35                    M            1                        RT-PCR

  Hamer et al. ([@B58])              Germany       26, Mar, 2020        Case report         59                    M            1                        RT-PCR

  Gupta et al. ([@B59])              India         10, Apr, 2020        Case series         40.3                  14M/7F       21                       RT-PCR

  Moreira et al. ([@B60])            Brazil        3, Apr, 2020         Case report         73                    M            1                        RT-PCR

  Gao et al. ([@B61])                China         24, Mar, 2020        Case series         54.6                  1M/2F        3                        RT-PCR

  Marchand-Senécal et al. ([@B62])   Canada        9, Mar, 2020         Case report         56                    M            1                        RT-PCR

  Lin et al. ([@B25])                China         11, Feb, 2020        Case series         37                    2M           2                        RT-PCR

  Makurumidze ([@B63])               Zimbabwe      2, Apr, 2020         Case series         NM                    2M/6F        8                        RT-PCR

  Li et al. ([@B64])                 China         7, Apr, 2020         Case series         8                     12M/10F      22                       RT-PCR

  Li et al. ([@B65])                 China         6, Apr, 2020         Case report         74                    F            1                        CT-Scan

  Li et al. ([@B66])                 China         30, Mar, 2020        Case series         61                    13M/12F      25                       RT-PCR

  Cheng et al. ([@B67])              Taiwan        16, Apr, 2020        Case report         55                    F            1                        RT-PCR

  Edrada et al. ([@B68])             Philippines   14, Apr, 2020        Case series         41.5                  1M/1F        2                        RT-PCR

  Feng et al. ([@B69])               China         7, Apr, 2020         Case report         34                    M            1                        CT-Scan

  Woznitza et al. ([@B70])           UK            2, Apr, 2020         Case series         78                    1M/2F        3                        RT-PCR

  Zeng et al. ([@B71])               China         5, Apr, 2020         Case report         63                    M            1                        RT-PCR

  Zhang et al. ([@B72])              China         18, Mar, 2020        Case report         64                    M            1                        RT-PCR

  Zhou et al. ([@B73])               China         3, Apr, 2020         Case series         NM                    1M/3F        4                        RT-PCR

  Torkian et al. ([@B74])            Iran          27, Mar, 2020        Case series         46                    2M/1F        3                        RT-PCR

  Tan et al. ([@B75])                China         3, Apr, 2020         Case series         7                     3M/7F        10                       RT-PCR

  Hase et al. ([@B76])               Japan         2, Apr, 2020         Case report         35                    F            1                        RT-PCR

  Huang et al. ([@B77])              Taiwan        19, Feb, 2020        Case series         73.7                  2F           2                        RT-PCR

  Hu et al. ([@B78])                 China         4, Mar, 2020         Case series         32.5                  8M/16F       24                       RT-PCR

  Hu et al. ([@B78])                 Italy         27, Mar, 2020        Case report         53                    F            1                        RT-PCR

  Kim et al. ([@B79])                South Korea   6, Apr, 2020         Case series         40                    15M/13F      28                       RT-PCR

  Kim et al. ([@B80])                South Korea   3, Feb, 2020         Case report         35                    F            1                        RT-PCR

  Kong et al. ([@B81])               South Korea   14, Feb, 2020        Case series         42.6                  15M/13F      28                       RT-PCR

  Lee et al. ([@B82])                Taiwan        10, Mar, 2020        Case report         46                    F            1                        RT-PCR

  Lescure et al. ([@B83])            France        27, Mar, 2020        Case series         47                    3M/2F        5                        RT-PCR

  Wissenberg et al. ([@B84])         Denmark       3, Apr, 2020         Case report         50                    M            1                        RT-PCR

  Li et al. ([@B85])                 China         1, Mar, 2020         Case series         55                    2M/1F        3                        RT-PCR
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of the case report and case series findings.

  -----------------------------------------------------------------------------------------------------------------------------
                            **Variables**                   **Number**\      **n/N[^\*^](#TN1){ref-type="table-fn"}**   **%**
                                                            **of studies**                                              
  ------------------------- ------------------------------- ---------------- ------------------------------------------ -------
  Comorbidities             Hypertension                    22               44/228                                     19

                            Cardiovascular disease          6                11/137                                     8

                            Diabetes                        17               27/241                                     11

                            Pulmonary disease               8                13/107                                     12

  Clinical manifestations   Fever                           68               248/401                                    62

                            Cough                           39               195/389                                    50

                            Dyspnea                         30               78/279                                     28

                            Myalgia/fatigue                 38               106/343                                    31

                            Sputum production               14               49/197                                     25

                            Sore throat                     20               48/164                                     29

                            Headache                        11               37/149                                     25

                            Diarrhea                        14               21/94                                      22

                            Nausea/vomiting                 8                17/84                                      20

                            Dizziness                       5                5/35                                       14

                            Rhinorrhea                      13               22/196                                     11

                            Chills                          4                4/13                                       31

  Laboratory findings       Lymphopenia                     24               83/185                                     45

                            Leukopenia                      17               38/150                                     25

                            Thrombocytopenia                8                26/69                                      38

                            High CRP                        18               118/197                                    60

                            High LDH                        14               34/77                                      44

                            High ESR                        10               17/42                                      40

                            High AST                        11               23/48                                      48

                            High ALT                        13               22/77                                      28.5

                            High creatinine kinase          8                9/44                                       20

                            High creatinine                 4                6/32                                       19

  CT                        Both of GGO and Consolidation   16               32/59                                      54

                            GGO without consolidation       20               48/60                                      80

                            Unilateral                      11               35/87                                      40

                            Bi lateral                      23               76/110                                     69

  Complications             ARDS                            11               18/86                                      21

                            Hospitalization                 30               77/83                                      93

  Outcomes                  Discharged                      23               137/205                                    67

                            Death                           10               17/108                                     16
  -----------------------------------------------------------------------------------------------------------------------------

*n, number of patients with any variables; N, the total number of patients with COVID-19*.

Common antiviral treatment modalities included lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). In [Table 3](#T3){ref-type="table"} we summarize all of the drugs used.

###### 

Treatment agents used in the included studies.

                                **Treatment**         **Agents**                   **Number of studies**   **n/N[^\*^](#TN2){ref-type="table-fn"}**   **%**
  ----------------------------- --------------------- ---------------------------- ----------------------- ------------------------------------------ -------
  Pharmacologic treatment       Antiviral drugs       Lopinavir                    6                       9/9                                        100
                                                      Arbidol hydrochloride        2                       6/6                                        100
                                                      Oseltamivir                  5                       1/1                                        100
                                                      Veletonavir                  1                       1/1                                        100
                                                      Remdesivir                   1                       1/1                                        100
                                                      Ribavirin                    1                       1/1                                        100
                                                      Ritonavir                    1                       1/1                                        100
                                                      Gancyclovir                  1                       1/1                                        100
                                Antibacterial drugs   Moxifloxacin                 4                       5/5                                        100
                                                      Vancomycin                   1                       1/1                                        100
                                                      Cefepime                     1                       1/1                                        100
                                                      Meropenem                    2                       2/2                                        100
                                                      Piperacillin tazobactam      2                       2/2                                        100
                                                      Sefoselis                    1                       1/1                                        100
                                                      Linezolid                    1                       1/1                                        100
                                                      Levofloxacin                 1                       1/2                                        50
                                Others                Methylprednisolone           5                       6/6                                        100
                                                      Ambroxol Hydrochloride       1                       1/1                                        100
                                                      Acetaminophen                2                       2/2                                        100
                                                      Ibuprofen                    2                       2/2                                        100
                                                      Intravenous Immunoglobulin   3                       4/7                                        57
                                                      Guaifenesin                  1                       1/1                                        100
                                                      Ondansetron                  1                       1/1                                        100
                                                      Interferon alpha-2b          2                       2/2                                        100
                                                      Herbal patent medicine       2                       3/3                                        100
  Non-pharmacologic treatment   Oxygen therapy        Non-invasive                 6                       10/10                                      100

*n, number of patients under treatment; N, the total number of patients with COVID-19*.

Discussion {#s5}
==========

The 2019 novel coronavirus has been declared a public health emergency worldwide. The World Health Organization (WHO) declared COVID-19 a pandemic affecting 110 countries around the world with a continued global spread. The 2019-nCoV is likely to be transmitted by asymptomatic individuals ([@B86]). Asymptomatic transfer leads to lower prevalence estimates and higher transmission rates in the community. Until universal screening and vaccination become available, it is necessary to trace close contacts of those testing positive for COVID-19 and quarantining contacts to prevent asymptomatic transmission.

According to the articles we included, 2019-nCoV can only be transferred from person to person ([@B87]). Chen et al. suggested that they had no evidence of vertical transmission from mother to child ([@B36]). Any person infected with 2019-nCoV can develop a clinical course of Covid-19. However, it is reported to cause the most severe symptoms such as respiratory failure in older men with comorbidities ([@B88]). Children, teenagers, and younger people mostly showed a mild presentation of the disease ([@B89]).

Based on our reviewed articles, hypertension, diabetes, cardiovascular disease, and pulmonary disease were the most common morbidities among COVID-19 patients. This point was also mentioned in Alraddadi et al. study about MERS-CoV patients ([@B90]). They showed that individuals with comorbidities like diabetes, smoking, and cardiovascular disease were associated with a more severe clinical course ([@B90]). According to Yang et al., chronic diseases can debilitate the immune system and make pro-inflammatory conditions, leading to more severe infection and subsequently higher mortality rates ([@B91]).

According to the included studies, the most common clinical manifestations were fever, cough, dyspnea, and myalgia or fatigue. Less common clinical manifestations included nausea or vomiting, dizziness, rhinorrhea, and chills. Liu et al. reported that infants had mild clinical manifestations and a better prognosis. Furthermore, some asymptomatic cases were seen among children.

The most common abnormal laboratory changes were lymphopenia, high concentrations of C-reactive protein, and elevated levels of aspartate aminotransferase; however, we do not know the exact pathogenesis and the reason for these alterations. Laboratory abnormalities may indicate the severity of disease and developing complications. According to Huang et al., most patients with secondary infection had a procalcitonin level \>0.5 ng/Ml and ICU patients had higher levels of prothrombin time and D-dimer ([@B92]). Also, Liu et al. mentioned using hypoalbuminemia, lymphopenia, high concentrations of CRP, and elevated LDH to predict the severity of acute lung injury ([@B3]). Higher levels of angiotensin II are also proposed to be related to acute lung injury ([@B3]). Meanwhile, non-survivors are suggested to have higher D-dimer and FDP levels, longer PT and aPTT, and lower fibrinogen and antithrombin levels ([@B93]).

CT scan as a diagnostic tool can be used to evaluate the severity of pulmonary involvement and monitor clinical progression. CT scan has good sensitivity and can be used to establish COVID-19 diagnosis in patients who are highly suspicious based on epidemiologic history and clinical manifestations but have negative PCR-based test results ([@B12], [@B94]). It is important to highlight that the CT scan can be normal during initial days, and a normal CT scan in a suspected case would never definitely rule out the diagnosis of COVID-19 ([@B95]). Moreover, the CT scan is dynamic in patients with COVID-19 and changes rapidly ([@B13], [@B17], [@B19]). The earliest abnormal finding in the CT scan is the appearance of ground-glass opacities in peripheral and sub-pleural areas ([@B96]). As the disease progresses, the GGO\'s will expand and distribute more, most commonly to the right lower lung lobes. Later findings include consolidations, paving patterns, thickening of lobar fissures, and adjacent pleura. Pleural effusion, hilar lymphadenopathies, and mediastinal lymphadenopathies are not common findings and have only been reported scarcely ([@B40]). Lung pathology can progress to a "white lung" with low functional capacity or heal with some fibrotic remnants ([@B40]). Dynamic changes in the lungs seen on CT imaging will continue even after the patient\'s discharge ([@B96]). CT scan findings have prognostic value in some patients, as Shi et al. have reported, deterioration on follow-up CT scan, old age, male sex, and underlying comorbidities are associated with poor prognosis.

ARDS was the most common complication among the confirmed COVID-19 patients; the development of ARDS increased the risk of patient mortality ([@B97]). Huang et al. reported that the median time from onset of symptoms to the development of ARDS was 9 days ([@B92]). Other complications were acute cardiac injury, acute kidney injury, secondary infection, and shock that leads to multiple organ failure ([@B98], [@B99]). ICU patients in comparison to non-ICU patients were also more likely to have complications ([@B100]). The mortality rate was higher in critically ill patients as well as in older patients with comorbidities and ARDS. Yang et al. reported that the median duration from ICU admission to death was 7 days ([@B97]). The window between the presentation to the time of ICU admission and/or development of ARDS is an optimal time for medical intervention.

Also, the results of the current study are in comparison with the recent large patient cohort studies in the aspect of comorbidities, clinical manifestations, laboratory, and radiological findings, however, there are some differences ([@B101], [@B102]). In a study by Richardson et al., a more detailed analysis of the patient\'s vital signs, ICU interventions, outcome characteristics, and risk factors were reported ([@B101]). According to their study, among the patients who were discharged or had died during hospitalization, 14.2% were treated in the ICU, 12.2% received invasive mechanical ventilation, 3.2% were treated with kidney replacement therapy, and 21% died. Moreover, Grasselli et al. indicated that Older patients (age ≥ 64 years) had higher mortality than younger patients (age ≤ 63 years) (36%vs 15%) ([@B102]).

There are many challenges in COVID-19 therapeutic strategies. There is currently no cure for COVID-19. However, pharmacologic and non-pharmacologic symptom management and supportive care measures should be given to all patients with symptomatic COVID-19. Other various therapeutic strategies have been trialed in patients with COVID-19 to slow disease progression. There is a paucity of data surrounding the efficacy of treatments. Of the case controls and case series we included, antiviral agents including HIV protease inhibitors (lopinavir and ritonavir) as well as anti-influenza compounds (oseltamivir and arbidol) were used as treatment regimens. Unfortunately, we didn\'t have enough information about the efficacy of each regimen; however, according to some studies, anti-HIV based medications could have benefits in more rapid improvement of clinical manifestations and decrease in viral load ([@B13], [@B16], [@B19]).

A limitation of this review relates to the potential risk of bias. Bias occurs in the case reports/series studies because their results are not representative and do not represent the truth. A further limitation is that the conclusions are limited due to the case reports and case series. We did not include observational studies and randomized controlled trial (RCT)/quasi-randomized studies, because another study being conducted by the authors. Furthermore, the focus of the reviewed case reports and case series was mainly on the clinical description of the patients with COVID-19, but detailed information on the treatment outcomes and medical consequences were rarely provided. Also, the case number included in this systematic review is low compared with the currently published patient cohort, and this may lead to the declining clinical significance of this manuscript. Finally, our results are limited to younger adults who had been hospitalized during the 4--5 first months of the COVID-19 pandemic.

In conclusion, we discussed the clinical symptoms, laboratory abnormalities, common comorbidities, imaging modalities, and potential therapeutic options in COVID-19. We indicated that the most common symptoms were fever, cough, and dyspnea, but some young infected cases had no signs or symptoms. ARDS was the most common reported complication and was associated with poor prognosis. In the wake of the COVID-19 pandemic, countries are scrambling to produce enough RT-PCR diagnostic tests. Diagnostic information from other surrogate markers would be valuable if markers proved to be sensitive and specific. Namely, we learned that laboratory data like CRP may not only be related to the severity of the disease, but it may be predictive of disease outcomes. Further studies are needed to relate quantified elevations in CRP to disease severity. Due to the high sensitivity of the CT scan, it is considered as a good diagnostic tool. However, it should be kept in mind that a normal CT scan will never rule out the diagnosis of COVID-19 in a highly suspicious case based on history and clinical findings. Lastly, there are different therapeutic strategies for COVID-19 patients, but we don\'t have enough data for their efficacy. Additional investigations including randomized controlled trials will be necessary to further our understanding of the treatment of COVID-19.
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